Released: · Last reviewed:
Plain-language definitions of every regulatory, clinical, and pharmacy term used in our reviews. 33 entries, cross-referenced and updated quarterly.
33 terms below. Each term is a citable entity with a stable anchor link — e.g., https://semaglutideglpone.com/glossary.html#semaglutide.
A once-weekly subcutaneous injectable peptide that selectively activates the GLP-1 (glucagon-like peptide-1) receptor — semaglutide is a single-receptor agonist, not dual. Manufactured by Novo Nordisk and sold as Ozempic (FDA-approved for type 2 diabetes) and Wegovy (FDA-approved for chronic weight management 2021; CV risk reduction 2024).
Brand name for semaglutide manufactured by Novo Nordisk, FDA-approved for type 2 diabetes mellitus (May 2022). Same active ingredient as Wegovy but different FDA label.
Brand name for semaglutide manufactured by Novo Nordisk, FDA-approved for chronic weight management (June 4, 2021) with a March 2024 label expansion adding cardiovascular risk reduction in adults with obesity and established CVD.
A once-weekly GLP-1 receptor agonist manufactured by Novo Nordisk. Brand names include Ozempic (type 2 diabetes), Wegovy (chronic weight management), and Rybelsus (oral type 2 diabetes formulation).
Patient-specific or office-stock semaglutide preparation dispensed by a 503A licensed compounding pharmacy or 503B FDA-registered outsourcing facility. Compounded semaglutide is NOT FDA-approved and is NOT the same as Ozempic or Wegovy.
A state-licensed compounding pharmacy under Section 503A of the Federal Food, Drug, and Cosmetic Act. Dispenses patient-specific compounded preparations under valid prescriptions, operates under USP <797> sterile compounding standards. Not FDA-inspected at the federal level (state oversight only).
An FDA-registered outsourcing facility under Section 503B of the Federal Food, Drug, and Cosmetic Act. Produces office-stock compounded medications under cGMP (current Good Manufacturing Practice). Subject to FDA inspection. Listed in the FDA's public Outsourcing Facility Registration database.
Pharmacy Compounding Accreditation Board. A voluntary third-party accreditation administered by the Accreditation Commission for Health Care (ACHC). PCAB accreditation signals adherence to USP <797> sterile compounding standards above and beyond state minimums.
United States Pharmacopeia chapter governing sterile compounding. Defines facility, equipment, personnel, environmental controls, and procedural standards for preparing sterile compounded medications including injectables.
United States Pharmacopeia chapter governing handling of hazardous drugs. Covers receipt, storage, compounding, dispensing, administration, and disposal.
United States Pharmacopeia chapter on sterility testing. Required as part of quality assurance for sterile compounded medications including injectable peptides.
United States Pharmacopeia chapter on bacterial endotoxins testing. Used to verify endotoxin content in sterile preparations.
High-Performance Liquid Chromatography test that measures the concentration of an active pharmaceutical ingredient in a finished compounded preparation. Confirms that the labeled potency matches actual content.
Document issued by a pharmacy or manufacturer for a specific lot or batch, listing test results including sterility, endotoxin, and potency.
A medication that has completed the FDA's New Drug Application (NDA) process and received marketing authorization for a specific indication, dose, and population. Compounded medications are NOT FDA-approved — they are dispensed under the Federal Food, Drug, and Cosmetic Act's compounding exemptions.
A third-party certification program that verifies online pharmacies and telehealth providers operate within applicable laws and best practices.
Class of medications that activate the glucagon-like peptide-1 receptor. Mechanism: enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces caloric intake. Examples: semaglutide (Ozempic, Wegovy), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity).
A medication that activates the glucose-dependent insulinotropic polypeptide receptor. GLP-1 is an incretin hormone that, like GLP-1, enhances glucose-dependent insulin secretion. Semaglutide is the first GLP-1 receptor agonist.
The stepwise increase of medication dose to a target maintenance dose. For Wegovy semaglutide: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, with at least 4 weeks at each step before escalating (maintenance from week 17). Slow titration reduces GI side-effect intensity.
Body Mass Index criteria for semaglutide weight-management prescribing. FDA Wegovy label: BMI ≥30, OR BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, OSA, cardiovascular disease).
Medullary thyroid carcinoma. A type of thyroid cancer arising from parafollicular C cells.
Multiple Endocrine Neoplasia syndrome type 2. A hereditary cancer syndrome characterized by medullary thyroid carcinoma. Contraindication for semaglutide.
The pivotal weight-loss trial for semaglutide in adults without diabetes (Wilding JP et al., NEJM 2021, n=1,961, PMID 33567185). Primary outcome: -14.9% mean change in body weight on semaglutide 2.4 mg over 68 weeks vs -2.4% on placebo.
Head-to-head trial of tirzepatide vs semaglutide 1 mg in adults with type 2 diabetes (NEJM 2021, PMID 34170647). Semaglutide produced approximately 47% greater weight loss and superior HbA1c reduction.
The FDA's most stringent warning, formerly called black-box warning, applied to medications with serious safety concerns. Semaglutide carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies; relevance to humans is unknown.
The provision of healthcare services using telecommunications technology, including video visits, asynchronous messaging, and remote monitoring. Telehealth prescribing of GLP-1 medications is permitted in all 50 U.S. states subject to standard practice requirements.
Clinical oversight by a Doctor of Medicine (MD) or Doctor of Osteopathic Medicine (DO).
Telehealth model where the patient never has a real-time video or phone visit with a clinician — all interaction is via written intake forms and messaging. Lower clinician-time cost, but a less rigorous standard for medication management.
Telehealth model where the patient pays the provider directly out-of-pocket (often with HSA/FSA), without billing insurance. Common for compounded medications and for brand-name medications when not covered by the patient's plan.
SemaglutideGLPOne.com's former v3.0 scoring rubric (replaced by v4.1 in November 2026) for semaglutide telehealth providers. 100 points total. 70% per-pillar threshold for transparency-compliant designation.
Element of the SemaglutideGLPOne.com v3.0 rubric (20 points).
Covers nutrition, behavior change, and titration support.
Pricing model where the monthly cost remains constant across the full medication titration schedule — no price increase as the patient escalates from 0.25 mg to 2.4 mg. NexLife's $95/mo (12-month plan) is flat across the entire 0.25–2.4 mg titration.